Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARGX-113-2207 pediatric generalized myasthenia gravis study
2023-506159-12-00Phase 3Authorised
- Sponsor
- argenx
- Start
- Sep 2024
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 13
01
Overview
Phase 3, open-label, single-arm trial of efgartigimod alfa in myasthenia gravis (MG), sponsored by argenx. Primary endpoints: Efgartigimod serum concentrations for PK modeling and Pharmacodynamic parameters (total IgG and AChR-Ab) for PK/PD modeling. Planned start Sep 2024; status: authorised.
02
Drugs
efgartigimod alfa
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on 2023-506159-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506159-12-00.